Presented at the ESC congress 2021 by: Prof. Stefan Anker, MD, PhD – Berlin, Germany
EMPEROR-Preserved enrolled 5988 patients (aged ≥18 years, NYHA class II-IV, elevated NT-proBNP, eGFR ≥20, T2DM and non-T2DM) from 622 centers in 23 countries to receive either empagliflozin 10 mg once daily + standard of care (n=2997), or placebo + standard of care (n=2991). The average age of included patients was 72 years, average LVEF was 54%, 45% were women and 49% had T2DM. The primary composite endpoint was time to first event of adjudicated CV death or adjudicated HF hospitalization. Secondary endpoints were total (first and recurrent) adjudicated HF hospitalizations, and slope of change in eGFR from baseline. Median follow-up was 26 months.
The SGLT2 inhibitor empagliflozin significantly reduced the primary composite endpoint of CV death or HF hospitalization by 21% in patients with HF and EF >40%, with and without diabetes. The effects of this treatment on the primary endpoint were consistent across all pre-specified subgroups, including LVEF and sex. Total (first and recurrent) HF hospitalizations were significantly reduced by 27% by empagliflozin. In addition, the rate of decline in eGFR was slower in patients in the empagliflozin group compared to patients in the placebo group.